Drug-carrying nanoparticles shrink venous malformations by 70% in mice

Drug-carrying nanoparticles significantly reduced venous malformations in mice by 70%, according to research published in Science Translational Medicine. The findings suggest a potential breakthrough in treating these conditions, which are characterized by abnormal vein growth that can lead to serious health complications. Venous malformations occur when the cells lining blood vessels grow excessively in areas where they shouldn’t. These abnormalities can appear at birth and often worsen as children grow. They vary in severity, ranging from minor cosmetic issues to severe functional impairments such as difficulty breathing, swallowing, or movement. Current treatment options are limited, with surgical removal being too dangerous for large malformations due to the risk of heavy bleeding. Patients often rely on oral medications like rapamycin to slow cell growth, but long-term use can lead to side effects, prompting some to discontinue treatment and allow malformations to progress. In response to these challenges, Dr. Kathleen “Kate” Cullion and Dr. Daniel Kohane, along with postdoctoral researcher Dr. Weimin Tang, explored alternative methods for delivering targeted therapy. Their approach centered on developing nanoparticles capable of carrying drugs directly to affected tissues. The idea stemmed from an earlier observation involving a patient whose contrast dye remained in a vascular malformation for two months. The dye, composed of nanoparticles typically not retained in healthy vessels, highlighted the abnormal leakage characteristic of malformed veins. Building on this insight, the researchers hypothesized that drug-loaded nanoparticles might similarly accumulate in venous malformations. Instead of using standard materials for nanoparticles, they engineered a specialized version incorporating a modified form of rapamycin. By linking multiple rapamycin molecules into structured bundles, they created stable, drug-delivering particles. These nanoparticles were further enhanced by incorporating another medication, ponatinib, within their internal cavities, enabling the simultaneous delivery of multiple therapeutic agents. In experiments conducted on mouse models of venous malformations, the researchers administered the customized nanoparticles and observed dramatic results. Compared to mice receiving the same drugs orally, those treated with the nanoparticle formulation showed a 70% reduction in malformation size after just 20 days. The effectiveness of the treatment was attributed to the unique design of the nanoparticles, which allowed rapamycin to exert its biological effects without requiring the release of free drug molecules, a process known to contribute to systemic side effects. Dr. Tang explained that the innovation lies in the structural composition of the nanoparticles, which retain the therapeutic properties of rapamycin while minimizing adverse effects. This novel formulation has the potential to be adapted for treating a variety of diseases beyond venous malformations, offering a versatile platform for targeted drug delivery. The research team intends to conduct extended monitoring of the nanoparticles to assess long-term efficacy and safety. Future studies will likely focus on refining the technology for human applications, addressing regulatory hurdles, and exploring broader clinical implications. The development marks a promising step forward in the treatment of vascular disorders, emphasizing the importance of innovative approaches in medical science.